lb1410
mAbexperimentalBi-specific
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2022 (NCT05357651)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07177716 | Phase 2/Phase 3 (Phase 3) | Oct 31, 2025 | Fudan University, Government of China |
| NCT06468358 | Phase 1/Phase 2 (Phase 2) | Jun 19, 2024 | Huazhong University of Science and Technology, L & L biopharma Co., Ltd. |
| NCT05357651 | Phase 1 | Jul 1, 2022 | Huazhong University of Science and Technology, L & L biopharma Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Huazhong University of Science and Technology | Academic/Hospital | 2 | 0 | 2 | 2022 |
| L & L biopharma Co., Ltd. | For profit | 2 | 2 | 2 | 2022 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Government of China | Government | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1